Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neurofibromatoses × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 34 Carcinoma, Hepatocellular 16 Neoplasm Metastasis 13 Prostatic Neoplasms 12 Neoplasms 8 Neuroendocrine Tumors 6 Carcinoma, Non-Small-Cell Lung 6 Brain Neoplasms 6 Kidney Neoplasms 5 Breast Neoplasms 5 Sarcoma, Ewing 4 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Multiple Myeloma 4 Clear-cell metastatic renal cell carcinoma 4 Carcinoma, Transitional Cell 4 Urinary Bladder Neoplasms 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Thyroid Diseases 2 Neurofibroma, Plexiform 2 Melanoma 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2

Interventions

Surveys and Questionnaires 2 talimogene laherparepvec 1 pirfenidone 1 nilotinib 1 mirdametinib 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Lidocaine 1 Lasers, Solid-State 1 Lasers 1 Imatinib Mesylate 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡